Last reviewed · How we verify
RSV prefusion F protein-based vaccine — Competitive Intelligence Brief
marketed
Viral protein subunit vaccine
Respiratory syncytial virus fusion (F) protein
Immunology
Vaccine
Live · refreshed every 30 min
Target snapshot
RSV prefusion F protein-based vaccine (rsv-prefusion-f-protein-based-vaccine) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RSV prefusion F protein-based vaccine TARGET | rsv-prefusion-f-protein-based-vaccine | Pfizer Inc. | marketed | Viral protein subunit vaccine | Respiratory syncytial virus fusion (F) protein |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Viral protein subunit vaccine class)
- Pfizer Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RSV prefusion F protein-based vaccine CI watch — RSS
- RSV prefusion F protein-based vaccine CI watch — Atom
- RSV prefusion F protein-based vaccine CI watch — JSON
- RSV prefusion F protein-based vaccine alone — RSS
- Whole Viral protein subunit vaccine class — RSS
Cite this brief
Drug Landscape (2026). RSV prefusion F protein-based vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/rsv-prefusion-f-protein-based-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab